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A B S T R A C TObjectives: Fidaxomicin is a novel treatment for Clostridium difficile
infections (CDIs). This new treatment, however, is associated with a
higher acquisition cost compared with alternatives. The objective of
this study was to evaluate the cost-effectiveness of fidaxomicin or oral
vancomycin for the treatment of CDIs. Methods: We performed a
cost-utility analysis comparing fidaxomicin with oral vancomycin for
the treatment of CDIs in the United States by creating a decision
analytic model from the third-party payer perspective. Results: The
incremental cost-effectiveness ratio with fidaxomicin compared with
oral vancomycin was $67,576/quality-adjusted life-year. A probabil-
istic Monte Carlo sensitivity analysis showed that fidaxomicin had an
80.2% chance of being cost-effective at a willingness-to-pay threshold
of $100,000/quality-adjusted life-year. Fidaxomicin remained cost-
effective under all fluctuations of both fidaxomicin and oral vanco-
mycin costs. The decision analytic model was sensitive to variationssee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.11.004
med.umich.edu.
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e – B2D321, Ann Arbor, MI 48109, USA.in clinical cure and recurrence rates. Secondary analyses revealed that
fidaxomicin was cost-effective in patients receiving concominant
antimicrobials, in patients with mild to moderate CDIs, and when
compared with oral metronidazole in patients with mild to moderate
disease. Fidaxomicin was dominated by oral vancomycin if CDI was
caused by the NAP1/Bl/027 Clostridium difficile strain and was domi-
nant in institutions that did not compound oral vancomycin.
Conclusion: Results of our model showed that fidaxomicin may be a
more cost-effective option for the treatment of CDIs when compared
with oral vancomycin under most scenarios tested.
Keywords: Clostridium difficile, Clostridium difficile–associated diarrhea,
cost-effectiveness, fidaxomicin, oral vancomycin, vancomycin.
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Clostridium difficile is the leading pathogen responsible for noso-
comial diarrhea in the United States [1]. It is estimated that
Clostridium difficile is responsible for causing more than 330,000
cases of infectious diarrhea in hospitalized patients annually
[2,3]. Furthermore, the incidence, severity, and mortality of
Clostridium difficile infections (CDIs) is rising [1,2,4]. For decades,
metronidazole and oral vancomycin have been cornerstones of
treatment for CDIs. Effectiveness of metronidazole, however, has
waned in recent years, and recurrent CDI is experienced in 20%
to 30% of the patients successfully treated with metronidazole
or vancomycin [5,6]. In addition to its impact on the patient,
CDIs increase health care costs because of extended lengths
of stay and rehospitalizations from recurrent disease [7].
The annual economic impact of CDIs in the United States has
been estimated to range between $750 million and $3.2 billion
[7–9].
Fidaxomicin is a macrocyclic antibiotic and the first treat-
ment approved for CDIs in over 20 years. Studies have shown
that fidaxomicin provides similar clinical cure rates comparedwith oral vancomycin for mild to severe CDIs, while being
superior at sustaining clinical response for up to 28 days [10].
Fidaxomicin has been found to have higher in vitro activity
against Clostridium difficile than does vancomycin, while having
minimal effect on normal gut flora [11,12]. These differences
between fidaxomicin and current standards make it a favorable
treatment option for CDIs. However, disparities between costs of
treatment are significant. The wholesale acquisition cost for a
10-day treatment course of fidaxomicin is $2800 [13]. The cost of
a 10-day treatment course with vancomycin pulvules (Vancocin)
is $1161 [13]; however, many institutions decrease this cost
substantially by compounding oral solution from the intrave-
nous (IV) powder. Given the high cost of therapy, fidaxomicin’s
use in clinical practice has been met with resistance and cost-
benefit analyses to compare the cost-effectiveness of fidaxomi-
cin with other standards of care have been called for [14,15]. To
date, the cost-effectiveness of treating CDIs with fidaxomicin
compared with other available agents has not been determined.
The objective of this study was to estimate the cost-
effectiveness of fidaxomicin or oral vancomycin for the treat-
ment of CDIs in the United States.Society for Pharmacoeconomics and Outcomes Research (ISPOR).
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We compared fidaxomicin with oral vancomycin for the treat-
ment of CDIs by creating a decision analytic model (DATA,
TreeAge Software, Inc., Williamstown, MA). Our analysis was
submitted to our institutional Investigational Review Board and
determined to be exempt according to policy. Our model was
based, in part, on previously published decision analytic models
that investigated the potential value of a C. difficile vaccine and
the overall attributable cost of CDIs [16,17]. These models incor-
porated the use of oral vancomycin and metronidazole in their
treatment algorithms. To investigate the clinical and economic
impact of fidaxomicin, we incorporated data published in a
randomized, open-label, multicenter trial conducted in the Uni-
ted States and Canada by Louie et al. [10]. The primary base-case
outcome measure was incremental cost/quality-adjusted life-
years (QALYs) from the payer perspective.
Model Design
Our model structure is displayed in Figure 1. Patients in each
treatment arm matched the intention-to-treat population from
the randomized multicenter trial and were excluded if they
presented with life-threatening or fulminant CDI, and toxic
megacolon [10]. Patients received a 10-day course of either
fidaxomicin or oral vancomycin for initial episodes of CDI or*
ig. 1 – Decision tree comparing fidaxomicin versus vancomycin
nfections. Treatment of initial CDI (fidaxomicin, metronidazole
reatment failure (regardless of inpatient or outpatient setting). ^
ailure. Hospitalization following treatment failure was assumed.
g every 6 hours for 10 days followed by a 4-week vancomycin
eeks after successful treatment. First recurrences were treated
reated with oral vancomycin 125 mg every 6 hours for 10 days
ancomycin 500 mg every 6 hours plus intravenous metronidazo
aper.first recurrence and were either treated as an outpatient or
hospitalized, regardless of disease severity. We assumed that all
patients who failed initial therapy received 3-day courses of
therapy and then changed to oral vancomycin 500 mg every 6
hours for an additional 10 days followed by a 4-week oral
vancomycin taper. Patients who failed therapy as an outpatient
required hospitalization. Recurrence was defined as reappear-
ance of CDIs within 4 weeks after successful treatment
[10,18].
Patients in all study arms with more than one recurrence
received therapy recommended by international guidelines,
oral vancomycin for 10 days followed by an oral vancomycin
taper [19]. Patients failing to respond to a therapy change or
treatment of a recurrence progressed to surgery or ongoing
pharmacologic therapy with 10 days of oral vancomycin 500 mg
every 6 hours and IV metronidazole followed by 4-week vanco-
mycin taper. Patients then either survived or died after surgery
or ongoing pharmacologic therapy. We modeled up to three
episodes of CDI, and patients were continued in the model until
cure with no recurrence or the decision for surgery was
required.Model Variables
All model variables are reported in Table 1. In the aforementioned
clinical trial, clinical cure in the modified intention-to-treattreatment in patients with CDIs. CDIs, Clostridium difficile
, or oral vancomycin), first or second recurrence, or first
Patient received 3 days of initial therapy before declared
After first failure, therapy changed to oral vancomycin 500
taper. yRecurrence defined as reappearance of CDI within 4
with the original selected agent. Second recurrences were
followed by a 4-week vancomycin taper. zTen days of oral
le 500 mg every 8 hours followed by a 4-week vancomycin
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 9 7 – 3 0 4 299population for outpatients was an equivalent 97.5%. The clinical
cure rate of inpatients was 81.4% in fidaxomicin patients and
78.1% in patients receiving oral vancomycin [10]. Recurrences
occurred more frequently in both outpatients receiving oral
vancomycin (12.8% vs. 22.7%) and hospitalized patients (17.6 vs.
27.4%) compared with those receiving fidaxomicin [10]. The
probability of recurrence was varied for first recurrences of CDI
to match those experienced with patients with previous episodes
of CDI in the Louie et al. trial [10].
The rate of surgery and subsequent death after surgery among
patients with treatment failure was assumed to be similar to that
in published retrospective reports and systematic reviews
[20,21,24–26]. Mortality rates from CDIs without surgery were
based on published sources [3,4,23].
The wholesale acquisition cost of antimicrobial therapy was
estimated from published dosing recommendations and sources
(i.e., fidaxomicin 200 mg twice daily and oral vancomycin 125 mg
every 6 hours) [13]. Many health systems compound oral vanco-
mycin from the IV product, decreasing the cost to an estimated
$20 per day [13]. Our inpatient base-case oral vancomycin cost
reflected this practice.
The total hospitalization cost was derived from the Agency for
Healthcare Research and Quality’s Healthcare Cost and Utilization
Project on CDIs [3]. The CDI principal diagnosis hospitalization
cost and associated costs of surgery were updated to 2011 US
dollars from the Medical Care Services section of the Consumer
Price Index from the Bureau of Labor Statistics [31]. It was
assumed that patients who failed therapy and required a change
in CDI treatment would require a longer hospital stay and
increased hospitalization costs. In these cases, we assessed an
incremental cost of hospitalization corresponding to the increased
stay, which was assumed to be three additional days per treat-
ment failure. The daily incremental cost of hospitalization was
determined from mean length of stay and hospitalization cost
reported by the Healthcare Cost and Utilization Project [3].
QALY measures for patients with CDIs are not well defined in
the literature. Previous CDI analyses have estimated utilities
associated with hospitalization or diarrheal diseases [17,32,33].
Given that no formal utility measure for CDIs have been deter-
mined by commonly accepted techniques such as time trade-off
or standard gamble, we derived our quality-of-life estimate for
CDIs from utility measures for grade 3 to 4 diarrhea associated
with certain chemotherapy treatments [27–29] as a surrogate for
determining the CDI-associated QALYs.
Patients with CDIs were estimated to be 59.9 years old, with
an estimated lifespan of an additional 23 years that served as our
time horizon for the model [34]. Patients who underwent total
colectomy were assigned a QALY weight corresponding to
patients with ileostomy [30]. All costs and utilities were dis-
counted by using a rate of 3%.
Sensitivity Analysis
Univariate sensitivity analyses assessed the impact of model
uncertainties and robustness of our analysis. Sensitivity ranges
were broadened on key variables to assess threshold analyses on
model results. In addition, we undertook a probabilistic sensitivity
analysis varying parameters in 10,000 Monte Carlo simulations.
Secondary Analyses
We performed several secondary analyses. Particular attention
was placed on medication acquisition cost by analyzing the use
of compounded oral vancomycin versus noncompounded medi-
cation during hospital stays through univariate sensitivity ana-
lysis. We also investigated the impact of known hospitalization
status prior to initial medication selection and the effect ofvariations in clinical cure and recurrence rates noted by investi-
gators in patients with NAP1/Bl/027 C. difficile strains [10].
We further analyzed the effect of concomitant antimicrobials
along with CDI treatment on clinical cure and recurrence rates.
We varied clinical cure and recurrence rates to match pooled
results reported in two separate prospective double-blinded,
randomized, parallel-group, noninferiority studies analyzed by
Mullane et al. [18]. This study reported wider differences in
clinical cure rates (90% for fidaxomicin and 79.4% for oral
vancomycin) and recurrence rates (16.9% for fidaxomicin and
29.2% for oral vancomycin) than did those reported previously
[18]. Study results were not reported on the basis of hospitaliza-
tion status or whether a patient had a previous episode of CDI;
therefore, inputs were used independent of hospitalization status
or a previous episode of CDI.
We analyzed the effect of disease severity on results of our
model. Patients in the trial by Louie et al. with severe disease had
a higher overall cure rate with oral vancomycin than with
fidaxomicin (88.6% vs. 82.1%), while the difference in recurrence
rates favored fidaxomicin (26.6% vs. 13%) [10]. Patients with mild
or moderate CDI experienced higher overall clinical cure rates
(92% vs. 83.8%) and lower rates of recurrences (16.8% vs. 24.4%)
with fidaxomicin than with oral vancomycin [10].
We further attempted to analyze the use of metronidazole in
patients with mild to moderate CDI compared with fidaxomicin
by assuming similar efficacy between metronidazole and oral
vancomycin and substituting the cost of oral metronidazole 500
mg three times daily for 10 days for that of oral vancomycin. The
inpatient cost of oral metronidazole is higher for inpatients when
oral vancomycin is compounded ($114 vs. $20 for a 10-day
course); however, the outpatient cost is significantly lower than
that of oral vancomycin [13]. As with our analysis of concomitant
antimicrobials, disease severity results were not reported on the
basis of hospitalization status or whether a patient had a
previous episode of CDI; therefore, clinical efficacy markers based
on disease severity were used independent of hospitalization
status or a previous episode of CDI.
Finally, we investigated the implications of an alternative CDI
utility measure by substituting our base-case CDI utility measure
(i.e., patients with grades 3–4 diarrhea associated with certain
chemotherapy treatments) with a point estimate of the utility of
patients undergoing active inflammatory bowel syndrome (0.674)
[35].Results
The results of our base-case and secondary analyses are dis-
played in Table 2. The incremental effectiveness gained from
utilizing fidaxomicin relative to oral vancomycin was 0.017
discounted QALYs (16.551 vs. 16.568). The cost per patient was
an estimated $1,117 higher in the fidaxomicin group ($12,306 vs.
$13,422). This suggested an incremental cost-effectiveness ratio
(ICER) of $67,576 by utilizing fidaxomicin versus oral vancomycin.
Sensitivity Analyses
A one-way sensitivity analysis showed that results were
impacted by a number of key variables based on a willingness-
to-pay of $100,000. Variations in fidaxomicin and oral vancomy-
cin recurrence rates (5%) impacted base-case results when the
fidaxomicin first-episode hospitalized recurrence rate increased
from 17.6% to 21.9%, or if the oral vancomycin recurrence rate
decreased from 27.4% to 23.3%. Results of our base case were also
impacted by CDI treatment response. Fidaxomicin was no longer
cost-effective at our willingness-to-pay threshold if the first
episode inpatient fidaxomicin cure rate dipped from 81.4% to
Table 1 – Decision analytic model variables.
Variable Base-case
value
Range Distribution Parameters
Mean  SD
Data
source
Costs ($)
Fidaxomicin 2,800 2,300–3,300 Gamma 2,800  280 [13]
Oral vancomycin
Outpatient 1,161 0–1,161 Gamma 1,161  116 [13]
Oral vancomycin 125 mg 20 0–1,000 Gamma 20  2 [13]
Oral vancomycin 500 mg 80 80–4,000 Gamma 80  8 [13]
Oral vancomycin tapery 812 0–812 Gamma 812  81 [13]
IV metronidazole 75 50–100 Gamma 75  7.5 [13]
Oral metronidazole 114 64–164 Gamma 114  11.4 [13]
Hospitalization 10,793 5,146–15,437 Normal 9,688  2,000 [3]
Per diem hospitalizationz 1,542 1,000–2,000 Normal 1,542  154 [3]
Increased hospital stay following
treatment failure (d)
3 1–10 Normal 3  1 Expert
opinion
CT scan 352 200–500 Normal 352  35 [20]
Colectomy 35,161 20,000–40,000 Beta 0.2  0.0025 [21]
Probabilities
Fidaxomicin
Cure
Inpatient 0.814 0.764–0.864 Beta 0.814  0.01 [10,18]
Outpatient 0.975 0.925–1 Beta 0.975  0.01 [10]
Mild to moderate cure 0.92 0.87–0.97 Beta 0.92  0.01 [10]
Severe cure 0.821 0.771–0.871 Beta 0.821  0.01 [10]
Concominant antimicrobials 0.9 0.85–0.95 Beta 0.9  0.01 [18]
NAP1/Bl/027 strains 0.787 0.737–0.837 Beta 0.787  0.01 [10]
Recurrence
Inpatient 0.176 0.126–0.226 Beta 0.176  0.01 [10,18]
Outpatient 0.128 0.078–0.178 Beta 0.128  0.01 [10]
Previous episode 0.214 0.164–0.264 Beta 0.214  0.01 [10]
Mild to moderate disease 0.168 0.118–0.218 Beta 0.168  0.01 [10]
Severe disease 0.13 0.08–0.18 Beta 0.13  0.01 [10]
Concominant antimicrobials 0.169 0.119–0.219 Beta 0.169  0.01 [18]
NAP1/Bl/027 strains 0.271 0.221–0.321 Beta 0.271  0.01 [10]
Oral vancomycin
Cure
Inpatient 0.781 0.731–0.831 Beta 0.78  0.01 [10,18]
Outpatient 0.975 0.75–1 Beta 0.975  0.01 [10]
Mild to moderate disease 0.839 0.789–0.889 Beta 0.839  0.01 [10]
Severe disease 0.886 0.836–0.936 Beta 0.886  0.01 [10]
Concominant antimicrobials 0.794 0.744–0.844 Beta 0.794  0.01 [18]
NAP1/Bl/027 strains 0.807 0.757–0.857 Beta 0.807  0.01 [10]
Recurrence
Inpatient 0.274 0.224–0.324 Beta 0.274  0.01 [10,18]
Outpatient 0.227 0.177–0.277 Beta 0.227  0.01 [10,18]
Previous episode 0.312 0.262–0.362 Beta 0.312  0.01 [10,18]
Mild to moderate disease 0.244 0.194–0.294 Beta 0.244  0.01 [10]
Severe disease 0.266 0.216–0.316 Beta 0.266  0.01 [10]
Concominant antimicrobials 0.292 0.242–0.342 Beta 0.292 (0.01) [18]
NAP1/Bl/027 strains 0.209 0.159–0.259 Beta 0.209  0.01 [10]
Vancomycin taper cure 0.69 0.49–0.89 Beta 0.69  0.1 [22]
Mortality CDI 0.026 0–0.13 Beta 0.0266  0.005 [3,4,23]
Colectomy 0.02 0–1 Beta 0.02  0.0025 [20,21,24–26]
Mortality colectomy 0.416 0.216–0.616 Beta 0.416  0.05 [20,21,24–26]
Utilities
QALY CDI 0.319 0–1 Beta 0.319  0.025 [27–29]
QALY colectomy 0.73 0–1 Beta 0.73  0.025 [30]
CDI, Clostridium difficile infection; IV, intravenous; QALY, quality-adjusted life-year.
 Cost per inpatient 10-d treatment course.
y Vancomycin taper: 125 mg twice per day for a week, 125 mg once per day for a week, and then 125 mg every 2 d for 2 wk.
z Determined from mean length of stay and hospitalization cost [3].
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Table 2 – Cost-effectiveness of fidaxomicin versus vancomycin treatment strategies.
Strategy Cost
($)
Incremental
cost ($)
Effect
(QALY)
Incremental
effect
Incremental C/E
(ICER) ($)
Base case
Oral vancomycin 12,306 16.551
Fidaxomicin 13,422 1,117 16.568 0.017 67,576
Initial episode hospitalization status
Outpatient
Oral vancomycin 4,294 16.581
Fidaxomicin 4,834 540 16.595 0.014 38,571
Inpatient
Oral vancomycin 15,579 16.539
Fidaxomicin 16,931 1,352 16.557 0.018 75,111
Mild to moderate disease
Oral vancomycin 12,214 16.555
Fidaxomicin 13,164 950 16.585 0.03 32,020
Metronidazole in mild to moderate
diseasey
Metronidazole 11,954 16.555
Fidaxomicin 13,156 1,139 16.585 0.03 40,513
Severe disease
Oral vancomycin 12,072 16.564
Fidaxomicin 13,494 1,442 16.568 0.004 352,994
NAP1/Bl/027 Clostridium difficile
strains
Oral vancomycin 12,044 16.551
Fidaxomicin 15,418 3,374 16.545 0.006 Dominated
Concominant antimicrobials
Oral vancomycin 13,333 16.536
Fidaxomicin 13,396 63 16.578 0.042 1,487
C/E, cost-effectiveness; ICER, incremental cost-effectiveness ratio; QALY; quality-adjusted life-year.
* Calculations for cost-effectiveness were performed by taking the incremental cost (difference between costs of compared strategies) divided
by the incremental effectiveness (difference between the effectiveness of the compared strategies).
y Efficacy variables for metronidazole assumed equivalent to those reported for oral vancomycin.
Fig. 2 – Acceptibility curve of fidaxomicin versus oral
vancomycin for the treatment of CDIs. This figure shows the
fraction of the time fidaxomicin or oral vancomycin was
cost-effective at various willingness-to-pay-per-QALY
thresholds in the 10,000 Monte-Carlo simulations. CDI,
Clostridium difficile infection; QALY, quality-adjusted life-
year.
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80.6%, or if the efficacy of oral vancomycin tapers increased from
69% to 78.5%.
The rate of hospitalization and the probability of CDI mortal-
ity also impacted results on the basis of our willingness-to-pay
measure. Fidaxomicin was no longer cost-effective at a
willingness-to-pay threshold of $100,000 if fewer than 20% of
the patients were treated in the outpatient setting or if CDI
mortality was less than 1.3%. No other variables, including
fidaxomicin and oral vancomycin medication costs, or the cost
and duration of hospitalization impacted base-case results.
Our probabilistic Monte Carlo sensitivity analysis performed
10,000 iterations of our model. The cost-effectiveness accept-
ability curve displayed in Figure 2 shows the proportion of the
time each therapy was cost-effective at varying willingness-to-
pay thresholds. Results from this analysis indicate that fidax-
omicin had an 80.2% chance of being cost-effective at
our $100,000 per QALY threshold, a 96.9% chance at $150,000
per QALY, and a 25.9% chance at a threshold of $50,000 per
QALY.
Secondary Analyses
Realizing that acquisition costs may vary with payer or institu-
tion, particular attention was placed on analysis in variations of
medication acquisition cost. Fidaxomicin dominated (i.e., lower
cost and increased efficacy) oral vancomycin when we substi-
tuted brand name oral vancomycin instead of compoundedproduct from IV formulations when patients were hospitalized.
Fidaxomicin remained cost-effective at a $100,000 per QALY
threshold under all fluctuations of both fidaxomicin and oral
vancomycin costs.
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rates for patients on concomitant antimicrobials reported by
Mullane et al. [18] showed an ICER of $1,487 utilizing fidaxomicin.
Oral vancomycin dominated fidaxomicin in situations involving
the NAP1/Bl/027 strain likely because of higher overall recurrence
rates in patients who received fidaxomicin. When hospitalization
status was known prior to medication selection, the ICER for
hospitalized patients depended greatly on whether a health
system utilized the compounded product. ($75,111/QALY with
compounded oral vancomycin and fidaxomicin dominated oral
vancomycin when brand name product was used.) If patients’
first episode of CDI occurred in the outpatient setting, our model
showed an ICER of $38,571.
Fidaxomicin was not cost-effective on the basis of our
willingness-to-pay threshold in patients with severe CDIs. The
ICER by utilizing fidaxomicin in patients with severe disease was
$352,994. Fidaxomicin was cost-effective when compared with
oral vancomycin in patients with mild to moderate CDIs (ICER of
$32,020) and also when the cost of oral metronidazole was
substituted for oral vancomycin (ICER $40,513) in patients with
mild to moderate disease.
Substituting our chosen CDI utility with a utility measure
used by Ladabaum [35] in an analysis of patients suffering from
active inflammatory bowel disease increased our base-case ICER
from $67,576 to $80,634. The univariate sensitivity analysis
showed that our model was robust to wide variations in the
CDI utility. No QALY variables tested along a wide sensitivity
range had the potential to impact results on the basis of our
willingness-to-pay threshold of $100,000/QALY.Discussion
To our knowledge, this is the first cost-utility analysis in the
primary literature investigating the use of fidaxomicin for the
treatment of CDI. We found the cost-effectiveness of fidaxomicin
versus oral vancomycin to be $67,576/QALY in the base case.
Willingness-to-pay thresholds for determining cost-effectiveness
are of some debate in today’s health care environment [36–38];
however, based on our willingness-to-pay threshold of $100,000,
fidaxomicin appears to be cost-effective in most situations
including whether patients were initially treated as outpatients,
received concomitant antimicrobials, and especially if brand
name oral vancomycin was used instead of compounding from
the IV product. Ultimately, those most likely to shoulder the
increased costs associated with fidaxomicin use, including health
care decision makers and payers, will assess their own will-
ingness to pay for these competing alternatives for the treatment
of CDIs.
Not surprisingly, recurrence and clinical cure rates were key
drivers of results in our base case. The difference in recurrence
rates between treatments reported in the literature ranges from
6.2% to 17.8%, with Louie et al. reporting a 9.8% difference in the
inpatient modified intention-to-treat population, and fidaxomi-
cin clinical cure rates were statistically noninferior than those of
oral vancomycin in a mixed population of varying disease
severity [10]. Fidaxomicin becomes less cost-effective as the
recurrence and clinical cure differences narrow.
International guidelines, developed prior to the introduction
of fidaxomicin, recommend a treatment stratification process
based on clinical markers of disease severity. Metronidazole is
the recommended agent to treat the initial episode or first
recurrence of mild to moderate CDI by international guidelines
[19] given its relatively equal efficacy to oral vancomycin and low
outpatient cost [13,39]; however, we are currently unaware of any
direct comparisons between metronidazole and fidaxomicin
reported in the literature. Oral vancomycin is recommended forpatients with severe disease; however, the benefit of oral vanco-
mycin over metronidazole in severe disease has been called into
question [19,40]. Our model indicated that fidaxomicin was not
cost-effective in patients with severe CDIs (ICER $352,994), likely
because clinical cure rates in the Louie et al. trial were higher
overall for patients with severe CDIs who received oral vanco-
mycin than in those who received fidaxomicin. Eighty-eight
percent of patients with severe disease who received oral vanco-
mycin were cured compared with 82.1% who received fidaxomi-
cin [10]. Reports of a clinical cure advantage for oral vancomycin
in patients with severe CDIs are conflicting. Clinical outcomes
favored fidaxomicin in patients with severe disease in a subse-
quent clinical trial by Cornely et al. [41] involving patients from
the United States, Canada, and Europe. Patients in this trial
treated with fidaxomicin experienced a 76.2% cure rate compared
with a 70.5% cure rate with oral vancomycin. This is a noteworthy
outlier because prescribers and decision makers may analyze the
role of fidaxomicin in varying patient populations [19]. Further
research is needed to confirm efficacy results in patients of
varying disease severity; however, based on results of our
secondary analyses utilizing information from the trial by Louie
et al., fidaxomicin was not cost-effective on the basis of our
willingness-to-pay threshold in patients with severe disease [10].
On the other hand, fidaxomicin fell well within standard
willingness-to-pay thresholds when we looked at patients with
mild to moderate disease receiving either oral vancomycin or oral
metronidazole.
We utilized a mixed population of both NAP1/Bl/027 and
non-NAP1/Bl/027 C. difficile strains in our base-case analysis. In
clinical trials, the hypervirulent NAP1/Bl/027 strain was asso-
ciated with lower rates of clinical cure and higher rates of
recurrence when treated with fidaxomicin and oral vancomy-
cin compared with non-NAP1/Bl/027 strains with higher overall
recurrences with fidaxomicin than with oral vancomycin in
patients with the NAP1/Bl/027 strain (27.1% vs. 20.9%) [10]. The
NAP1/Bl/027 strain has been associated with causing more
severe disease and higher rates of mortality during CDI epi-
demics [42,43]; however, researchers have not found the NAP1/
Bl/027 strain to be associated with more severe symptoms,
morbidity, mortality, or higher relapse rates during nonepi-
demics [44–47]. Our results revealed that another population in
which oral vancomycin showed an advantage compared with
fidaxomicin was in patients with Bl-strain C. difficile.
Our model contained a number of assumptions that could
bias our model against fidaxomicin. We utilized the wholesale
acquisition cost of fidaxomicin, which may overestimate the
actual acquisition cost. Many health systems in the United States
may qualify for medication pricing via the Health Resources and
Services Administration’s 340B Drug Pricing Program [48], which
is likely lower than the $280/d cost for fidaxomicin used in our
model. At the same time, we utilized a compounded oral
vancomycin cost during all hospitalizations. Some health sys-
tems may not compound oral vancomycin, or the actual payer
charge may not reflect this practice. In addition, patients may not
receive their entire course of therapy as inpatients, therefore,
requiring a few days of noncompounded product as an out-
patient. Fidaxomicin was cost-effective at our $100,000 per QALY
threshold through all variations in both fidaxomicin and oral
vancomycin costs. We report various cost scenarios that may
increase the generalizability of our study on the basis of practice
patterns of payer organizations.
In experimental and observational studies, vancomycin and
metronidazole use has been associated with increased intestinal
colonization with vancomycin-resistant enterococci or extended
spectrum beta-lactamase-producing Klebsiella pneumoniae
whereas fidaxomicin has not [49]. We did not include the risk
of colonization and the corresponding risk of infection into our
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 9 7 – 3 0 4 303model as this treatment effect is yet to be verified by larger
studies. Vancomycin-resistant enterococci and other drug-
resistant organism infections are a significant source of morbid-
ity and mortality for patients and can lead to increased health
care costs [50–53]. We feel that further research is needed to
predict the collateral damage, or lack thereof, associated with
fidaxomicin. By not including the risks of colonization, the
chance of the development of associated infections, and the
associated increased costs again biased our model, likely sub-
stantially, against fidaxomicin.
Our study contains a number of limitations in addition to the
inherent limitations associated with economic modeling. Results
reported by Louie et al. contained a mixed population composed
of patients experiencing their first CDI episode and also those
who had a previous episode of CDI. We were unable to accurately
estimate recurrence rates in patients with primary disease and in
those with previous episodes of CDI when separated by inpatient
and outpatient status. Therefore, we utilized combined efficacy
rates in this population, which may have overestimated recur-
rence rates in the outpatient population and underestimated in
inpatients. Another limitation is the fact that published treat-
ment guidelines do not endorse a single treatment strategy for
patients who fail treatment or patients with recurrences follow-
ing treatment failures. Treatment recommendations in these
populations may vary between institutions and prescribers, and
little published research is available to guide prescribers in this
area. As such, we relied on expert opinion or studies with lower
levels of evidence when modeling prescriber choices and efficacy
reports in these patient populations. Similarly, our lack of a
consistent CDI QALY measure caused us to rely on expert opinion
to explore alternative disease states with reported utility mea-
sures that could attempt to replicate CDI severity. We acknowl-
edge these as limitations and look forward to further research or
consensus guidance in these areas.
We chose to not incorporate costs of adverse events asso-
ciated with the use of either medication. During clinical trials,
adverse events possibly or definitely associated with treatment
were found to be 9.7% in the fidaxomicin and 9.0% in the
vancomycin groups. Most symptoms were nonspecific or gastro-
intestinal [10]. Serious adverse events associated with either
treatment were rare and difficult to value and likely would not
affect overall results.
The results of our analysis were robust to changes in most
variables within our predefined sensitivity ranges. In addition to
clinical cure and recurrence rates, our model was sensitive to the
rate of hospitalization and mortality from CDIs. Neither the cost
of hospitalization nor additional hospital stay due to treatment
failures had the potential to impact base-case results. We
assumed the cost of hospitalization for CDIs to be $10,793 to
reflect the management of CDIs as the primary diagnosis, while
the hospitalization cost has been found to be as high as $31,500
for CDIs as a secondary diagnosis [3]. Fidaxomicin remained cost-
effective at our willingness-to-pay threshold when a lower cost of
hospitalization was used and the ICER by utilizing fidaxomicin
decreased with higher hospitalization costs. We assumed three
additional treatment days prior to changing medications because
of treatment failures and actual practice is likely to vary among
institutions or prescribers. We varied the number of incremental
days per failure up to 10 additional days and fidaxomicin
remained cost-effective on the basis of our willingness-to-pay
threshold under all incremental durations tested.
We chose to undertake this study from the payer perspective
utilizing data from the United States. We acknowledge that
results may be vastly different when one considers alternative
perspectives, time courses, and efficacy measures. Similarly,
fidaxomicin was approved for the treatment of CDIs by the
European Commission in December 2011 and results from a trialinvolving European patients were published in 2012 [41]. Cost-
effectiveness analyses using variables unique to individual coun-
tries are also needed. Prospective studies are needed to confirm
results of this analysis and to further investigate the efficacy of
fidaxomicin and other CDI treatment options in varying patient
populations and disease states including high-risk patients with
multiple risk factors for recurrent disease, refractory CDI, and
multiple recurrences and in immunosuppressed patients. Finally,
we agree with Wilcox [54] that a prospectively validated, simple
yet accurate scoring system or laboratory test is needed to predict
recurrent disease and potentially decrease the overall cost of
treating CDIs.
Fidaxomicin is the first novel compound developed for the
treatment of CDIs in many years and is a welcome addition to the
limited antimicrobial armamentarium for the treatment of CDIs.
The increased acquisition cost compared with available treat-
ments is significant; however, results of our analysis reveal that
fidaxomicin is a cost-effective alternative for the treatment of
CDIs under most scenarios examined. Results provide health care
decision makers additional information when considering CDI
treatments in today’s cost-conscious health care environment.Acknowledgments
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